Mindray Acquires HyTest from Summa Equity for €545 Million
May 16, 2021
Mindray has signed a definitive agreement to acquire HyTest, a Finland-based developer and manufacturer of high-performance antibodies and antigens for in-vitro diagnostics, from private equity owner Summa Equity for approximately €545 million. The deal, subject to customary regulatory approvals, is expected to close in the second half of the year and expands Mindray’s capabilities and product portfolio in IVD reagents and raw materials.
- Buyers
- Mindray
- Targets
- HyTest
- Sellers
- Summa Equity
- Industry
- Medical Devices
- Location
- Southwest Finland, Finland
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Edgewater Capital Partners Acquires Haematologic Technologies
October 11, 2019
Biotechnology
Edgewater Capital Partners has entered into an agreement to acquire Haematologic Technologies Incorporated, a Vermont-based provider of biologic products, reagents and GMP-compliant assay development and testing services for the biopharmaceutical industry. Edgewater said it will support HTI's next phase of growth and build the company as a premier outsourced services partner for biologics; financial terms were not disclosed.
-
HORIBA Acquires MedTest Holdings (MedTest Dx, Pointe Scientific, Clinitox, Medical Laboratory Solutions)
February 3, 2021
Medical Devices
HORIBA, Ltd. (through HORIBA Instruments) acquired MedTest Holdings, Inc., including subsidiaries MedTest Dx, Pointe Scientific, Clinitox Diagnostix and Medical Laboratory Solutions, to expand HORIBA Medical's clinical chemistry and IVD reagent and instrument capabilities. The deal combines HORIBA Medical's Yumizen brand and distribution with MedTest/Pointe Scientific's R&D, manufacturing and regulatory (FDA 510(k)/CLIA) expertise to address multidisciplinary in‑vitro diagnostics (IVD) customer requirements.
-
Biogen Acquires Human Immunology Biosciences for up to $1.8B
May 22, 2024
Biotechnology
Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.
-
Hologic, Inc. Acquires Mobidiag Oy
June 17, 2021
Medical Devices
Hologic, Inc. has completed the acquisition of Mobidiag Oy, a Finnish developer of near‑patient molecular diagnostic instruments and tests, for approximately $808 million. The deal expands Hologic's diagnostics capabilities by adding Mobidiag's Amplidiag and Novodiag platforms for rapid, multiplexed acute‑care testing and broadens Hologic's global diagnostics footprint.
-
Atlas Antibodies Acquires HistoCyte Laboratories Ltd
February 1, 2021
Medical Devices
Atlas Antibodies AB has signed an agreement to acquire UK-based HistoCyte Laboratories Ltd, a maker of cell-line control materials for immunohistochemical assays. The deal combines Atlas's proteome-wide antibody reagent portfolio with HistoCyte's novel control materials to expand diagnostic and research offerings; closing was expected in early March 2021.
-
Summa Equity Acquires Majority Stake in Axion BioSystems
July 15, 2021
Medical Devices
Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.